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FortiColos – a multicentre study using
bovine colostrum as a fortifier to human
milk in very preterm infants: study protocol
for a randomised controlled pilot trial
Agnethe M. Ahnfeldt1†, Nana Hyldig4,5†, Yanqi Li1, Susanne Soendergaard Kappel1,3, Lise Aunsholdt3,
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Abstract
Background: Very preterm infants (< 32 weeks gestation) have a relatively high nutrient requirement for growth
and development. The composition of human milk is often inadequate to ensure optimal growth so it is common
to fortify human milk for very preterm infants with nutrient fortifiers based on bovine milk. However, there are
concerns that bovine milk-based fortifiers may increase the risk of feeding intolerance, necrotizing enterocolitis and
late-onset sepsis. We hypothesize that a bovine colostrum-based product is a suitable alternative to bovine milk-
based products when used as a fortifier to human milk in very preterm infants.
Methods/Design: In an open-label multicentre randomised controlled pilot trial, 200 very preterm infants (26 + 0 to
30 + 6 weeks gestation at birth) will be randomly allocated to a bovine colostrum-based or a bovine milk-based
fortifier added to mother’s own milk and/or human donor milk. Outcomes are growth rate, incidence of necrotizing
enterocolitis and late-onset sepsis, a series of paraclinical endpoints, and practical feasibility of using the novel
fortifier for very preterm infants.
Discussion: The optimal enteral diet and feeding regimen for very preterm infants remain debated; this clinical trial
will document the feasibility, safety and preliminary efficacy of using bovine colostrum, rich in nutrients and bioactive
factors, as a novel fortifier for human milk to very preterm infants. Data on infant growth, metabolism, gut function and
immunity will be assessed from clinical data as well as blood and stool samples.
Trial registration: Registered retrospectively 25 May 2018 at ClinicalTrials.gov: NCT03537365.
Keywords: Bovine colostrum, bovine colostrum-based fortifier, bovine milk-based fortifier, fortification of human milk,
mother’s own milk, human donor milk, nutrition, growth, very preterm infants, necrotizing enterocolitis, late-onset
sepsis, feeding intolerance
Background
Very preterm infants (< 32 weeks gestation) have a rela-
tively high nutrient requirement for growth and develop-
ment. Poor growth in the postnatal period is associated
with later impaired neurodevelopment [1–3], metabolic
disorders [4] and short stature [5]. Provision of adequate
energy and nutrients (e.g. protein, minerals, vitamins)
helps to prevent postnatal growth restriction [6]. Paren-
teral nutrition may initially be needed to support optimal
nutrient intake in very preterm infants. Long-term paren-
teral nutrition is associated with higher risk of late-onset
sepsis (LOS) [7], while a too fast increase in enteral nutri-
tion may predispose to feeding intolerance and necrotiz-
ing enterocolitis (NEC) [8]. Further, excessive weight gain
may predispose to metabolic and cardiovascular disorders
later in life [9, 10]. It therefore remains a difficult task to
optimize the transition to enteral nutrition, achieve
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adequate nutrient intake, minimise LOS and NEC, and
achieve optimal growth in the postnatal period of very
preterm infants [6, 7, 11].
Mother’s own milk is considered the best source of en-
teral nutrition for very preterm infants [12], and if mother’s
own milk is not available or production is insufficient dur-
ing the first weeks after preterm birth, human donor milk
is recommended as the second choice. A protein intake of
3.5–4.5 g/kg/day is suggested for extremely and very
preterm infants to achieve a postnatal growth rate similar
to the intrauterine growth rate [13]. However, this recom-
mended level of protein intake is seldom met by feeding on
mother’s own milk and/or human donor milk alone. Fur-
thermore, the amount of energy and protein varies widely
in human milk both between mothers and throughout the
lactation period [14, 15]. It has therefore become standard
practice to enrich mother’s own milk and human donor
milk with a nutrient fortifier to support growth, bone
mineralization and neurodevelopment in very preterm
infants [3, 16, 17].
Concerns have been raised that currently available forti-
fiers, based on bovine milk products derived from proc-
essed bovine milk and vegetable components, may increase
feeding intolerance and the risk of developing NEC [18,
19]. A fortifier based on concentrated human donor milk
has recently become available and very preterm infants fed
exclusively human milk (mother’s own milk and/or human
donor milk) fortified with the human donor milk product
showed lower incidences of NEC and sepsis compared with
infants fed diets partly or fully consisting of bovine-based
products [20–22]. However, it remains unclear if bovine
milk-based fortifiers (BMF) added to human milk (without
any supplemental formula feeding) is a problem, and the
high cost of the fortifier based on human milk may prevent
its widespread use in the future [23]. A recent randomised
control trial in preterm infants showed no difference in
feeding tolerance when a human milk-based fortifier was
compared with a bovine milk-based fortifier and vegetable
products [24]. Fortifiers based on milk from non-bovine
species are also being tested (e.g. donkey) to investigate
whether bovine milk protein constitutes a specific problem
for preterm infants [25].
Bovine colostrum (BC) is the first milk from cows
after parturition and, like human colostrum, it contains
much higher levels of protein, antimicrobial factors, im-
munoregulatory factors and trophic factors than mature
milk (e.g. immunoglubolins, lactoferrin, lysozyme, lac-
toperoxidase, osteopontin, transforming growth factor,
insulin-like growth factors, epidermal growth factor)
[26]. These components may improve gut maturation,
protection and nutrient assimilation, even across spe-
cies. Used as the first feed or as a fortifier to human
milk, intact BC improves gut maturation and NEC
resistance in preterm pigs [27–29] and preliminary
studies indicate that it is well tolerated also in preterm
infants [30, 31].
On this background, we hypothesize that a powdered
BC-based fortifier (BCF) for human milk can induce
similar growth and better NEC and LOS resistance than
a conventional, powdered BMF. A pilot trial is required
to test the practical feasibility and safety of using BCF,
e.g. that growth rates and clinical variables are similar to
those of BMF. Further, the pilot trial is required to cal-
culate the sample size for a later, larger randomised con-
trol trial with NEC and LOS as the primary outcomes.
Methods/Design
Study setting
This study is designed as an open-label randomised con-
trolled multicentre pilot trial of BCF compared with a
conventional BMF, both used to fortify human milk, i.e.
mother’s own milk and/or human donor milk (Figs. 1 and
2).
Study population
Study participants will be recruited from multiple neo-
natal intensive care units and neonatal care units in
Denmark. Very preterm infants born between gestational
age 26 + 0 and 30 + 6 weeks will be recruited if they are
in need of nutrient fortification to achieve optimal
growth rates, as judged by the responsible clinical
personnel. The infant should stay at one of the partici-
pating units at least until postmenstrual age (gestational
age plus weeks and/or days since birth) 34 + 6 weeks, be-
fore being transferred to a non-participating unit. Infants
participating in an early discharge programme (dis-
charged home for breastfeeding establishment with a
nasogastric tube) can also participate in the study until
discharged. Exclusion criteria are major congenital
anomalies and birth defects, gastrointestinal surgery and
formula feeding prior to randomisation.
Intervention
Introduction of enteral nutrition will follow the standard
practice at the participating neonatal care unit and neo-
natal intensive care units. At all units, the mothers are
encouraged to express breast milk as soon as possible
after birth and continue expressing, so the infants will
receive as much mother’s own milk as possible. Human
donor milk will be used when mother’s own milk is not
available or insufficient in amount. Fortification of hu-
man milk (both mother’s own milk and/or human donor
milk) will start when enteral nutrition reaches a volume
of at least 100 and maximum 140mL/kg/day, unless
blood urea nitrogen (BUN) values are > 5 mmol/L. In
such cases, fortification may be delayed and started at
higher feeding volumes. Eligible infants will be randomly
assigned to one of two groups, namely human milk will
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be fortified with either BCF (Bovine colostrum, Biofiber,
Gesten, Denmark) or a commercially available BMF
(PreNAN FM85, Nestlé, Vevey, Switzerland). Table 1
shows the composition of macronutrients and bioactive
components in BCF compared with the values in mature
bovine milk, human colostrum, human term and pre-
term milk [32–39]. The control BMF fortifier is cur-
rently used for very preterm infants at all Danish
neonatal units. The nutrient compositions of the two
fortifiers are compared in Table 2. On the first day of
intervention, 1.0 g of fortification is added to 100 mL of
human milk in both groups. In the following days, the
amount of BCF and BMF is upregulated with a planned
speed to ensure that the same protein level is provided
from both fortifiers to a maximum of 1.4 g per 100 mL
of human milk, corresponding to 2.8 g of BCF and 4.0 g
of BMF. The units may choose to individualise the forti-
fication level according to the amount of protein in
mother’s own milk measured on a weekly basis, or they
may use standard fortification based on an assumed
composition of human milk [15]. The infants will receive
fortified human milk as long as additional protein is
needed, according to postnatal growth rates and breast-
feeding establishment. Both groups will be supplemented
with phosphorus, iron, multivitamins and vitamin D ac-
cording to standard recommendations.
Data collection and management
We will collect data from birth until final discharge. During
the intervention period, nurses will record information
regarding feeding volumes, residuals (volume and colour),
and appearance of stomach (any distension, colour and ves-
sel appearance) and stools (amount, colour and texture),
using a modified version of the Infant Stool Form Scale
[40] and the COMFORTneo Scale [41]. Data will be col-
lected using paper case report forms which are entered into
Fig. 1 Flow of participants and data collection in the FortiColos Study
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an online database (REDCap) [42]. The electronic database
is stored in a secure server at the Region of Southern
Denmark.
Blood and stool samples will be collected before the first
fortified meal, and at 1 and 2 weeks after start of fortifica-
tion, and stored at − 60 °C to − 80 °C. All samples will sub-
sequently be transported to a centralized biobank at the
University of Copenhagen for later analysis. Randomised
infants, discontinued early from the randomised type of
fortification (according to clinical judgment or parental re-
quest, will with parental acceptance continue collecting
data), will be considered as ‘off-study fortifier’ but ‘on
study’ and followed until discharge with sampling of blood
and faeces, if possible. Discontinuation due to withdrawal
of parental consent or loss to follow-up will also be
recorded.
Outcome measures
Primary outcome
The primary clinical focus in this pilot trial is the evalu-
ation of both body growth and incidence of NEC and LOS.
The proposed primary outcomes in a later larger-scale
randomised controlled trial will be NEC- and LOS-free
survival, but this pilot study does not allow for a full inves-
tigation of these endpoints with adequate statistical power.
Since the main reason to fortify human milk is to improve
Fig. 2 SPIRIT figure for FortiColos showing the schedule of enrolment, interventions and assessments
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postnatal growth rates, it will also be important to docu-
ment whether the novel BCF fortifier can induce infant
growth rates similar to those of the conventional BMF.
Body growth will be recorded as weight gain in grams from
birth to discharge from hospital. Weight at different time
points will be calculated into z-scores according to Niklas-
son and Albertsson-Wikland [43]. Delta z-scores will be
used to evaluate growth and for comparison between
groups. NEC is defined as Bell’s stage II or above [44]. LOS
is defined as clinical signs of infection (e.g. increased heart
rate, increased need of oxygen and episodes with apnoea,
fluctuation of temperature and/or pale colour of the skin)
with or without increased CRP after age 2 days, and anti-
biotic treatment for ≥ 5 days, or shorter if the infant died,
with or without one positive bacterial culture in blood or
cerebral spinal fluid.
Secondary outcomes
A series of secondary outcomes will be evaluated at differ-
ent time points. Days on parenteral nutrition are defined
as number of days the infant receives intravenous intakes
of protein and/or lipid and/or glucose. Feeding volume
when fortification is initiated, amount of fortification at
each meal and duration of fortification will be registered.
Time to reach full enteral nutrition (in days) is defined as
the time when at least 150mL/kg/d is reached and paren-
teral nutrition has been discontinued. Feeding intolerance
is defined as proportion of days with a nutrition volume
less than 50% of the total planned volume per day, mea-
sured during intervention. Stomach, residuals and stool
appearance will be evaluated each day during intervention.
Length of hospital stay is defined as days from birth until
final discharge. Body length and head circumference will
be measured from birth and once a week during
Table 1 Macronutrient composition and bioactive factors in bovine and human colostrum, term and preterm milk
Bovine
colostrum
Human
colostrum
Preterm human
colostrum
Term bovine
milk
Term human
milk
Preterm human
milk
Protein, g/L 60–135a 11–32c 19f 34c 9–12g 12.7f
Casein, g/L 26b 3.0–5.6c 2~30c 4–4.8g
Whey, g/L 35–119a 4.3–11.1c 4~50c 6–7.2g
α-Lactalbumin, g/L 2.04c 2.56c 1–1.5c 2–3c
β-Lactoglobulin, g/L 14.3c Nonec 3–4c Nonec
Lactoferrin, g/L 1.0–2.0c 5.0–7.0c 0.01–0.1c 1.0–2.0c
Immunoglobulins, g/L 20–150c 1.14–20c 0.6–1.0c 1.2c
Lactoperoxidase, mg/L 11–45c 5.17c 13–30c 5.17c
Osteopontin, mg/L Not determinedc 1493.4c 18c 138c
Lysozyme, mg/L 0.14–0.7c 270–430c 0.07–0.6c 160–460c
Superoxide dismutase, U/mL 0.06–2.88c 18.7–22.5c 0.06–2.88c 11.2c
Platelet-activating factor-acetylhydroxylase, μg/L Nonec 0.95–1.19c Nonec 1.16–1.21c
Alkaline phosphatase, μkat/L 6.84h 1.79c 4.49c 0.92c
Transforming growth factor-β, μg/L 150–1150c 1366c 13–71c 953c
Insulin-like growth-I, μg/L 49–2000c 29–49c 4–150c 3–6c
Insulin-like growth-II, μg/L 400–600c 10.5c 50–100c 35c
Epidermal growth factor, μg/L 4–324.2c 35–438c 2–155c 20–111c
Lactose, g/L 18.9–32a 44–59d 57–74f 49a 67–78g 73f
Fat, g/L 50–80a 20–29e 26f 37a 32–3g 35f
aAbd El-Fattah AM [32], bKorhonen HJ [33], cChatterton DEW [34], dEspinosa-Martos I [35], eJensen RG [36], fBoyce C [37], gBallard O [38], hZanker IA [39]
Table 2 Amount of energy, protein, minerals and vitamins in
PreNAN FM85 powder and the used bovine colostrum powder,
as indicated when maximum fortification is reached
Bovine colostrum
Pr. 2.8 g
PreNAN FM85
Pr. 4.0 g
Energy, kcal 13 17
Protein, g 1.4 1.4
Carbohydrate, g 0.6 1.3
Fat, g 0.6 0.72
Calcium, mg 25.8 76
Phosphorus, mg 22.7 44
Zink, mg 0.20 0.96
Iron, mg 0 1.8
Vitamin D3, μg 0 3.5
Vitamin A, μg 27.8 333
Vitamin E, mg 0.05 3.8
Vitamin C, mg 0 19
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intervention and at final discharge. BUN, blood minerals
and blood haemoglobin will be collected from medical re-
cords during the intervention period. Plasma levels of
amino acids, intestinal fatty acid binding protein, neutro-
phil extracellular trap components, lactoferrin and inter-
leukin (IL) will be measured prior to and 1 and 2 weeks
after start of fortification. Faecal composition of micro-
biota and faecal levels of IL-8, calprotectin (S100-A8/9)
and metabolites (short-chain fatty acids) will be measured
in faecal samples taken just prior to and 7 and 14 days
after start of fortification.
Randomisation and blinding
Each infant will be randomly allocated by a local member
of the research team who accesses an online randomisa-
tion programme (REDCap) via a server at the Region of
Southern Denmark. A computer-generated randomisation
sequence will be used with a 1:1 allocation, random block
sizes of 4–6, and stratified by small-for-gestational-age
(SGA, yes/no), where SGA is defined as a birth weight
z-score less than two standard deviations [44]. The ran-
dom allocation sequence will be generated by an external
data manager not involved in the trial. In case of multiple
births, all siblings will be allocated to the same group, ran-
domised by the first-born infant. Blinding is not possible
in this trial, and the two powdered fortifiers can be distin-
guished by colour and texture. The schedule of enrolment,
intervention and data collection are described in Figs. 1 and
2.
Statistical analysis
Sample size
The sample size in this pilot trial is set at n = 100 for each
group (total 200) based on pragmatic evaluations for
comparison between groups on infant growth, laboratory
outcomes (clinical and paraclinical) and the study feasibility
outcomes. If the primary endpoint had been NEC- and
LOS-free survival, the total sample size should have been
1498 participants according to a power calculation, based
on an aim to test a 50% reduction in NEC incidence and a
25% reduction in LOS incidence at discharge with 80%
power and a two-sided 0.05 level of significance, and
assuming a NEC incidence of 6% and a LOS incidence of
30%.
Analysis
Statistical analyses will be performed as both intention-
to-treat and per protocol analyses. Per protocol analysis
will include infants treated with the randomised type of
fortifier for a minimum time of 2 weeks. Continuous
outcomes will be summarized as mean and standard devi-
ation (e.g. body weight) or median and interquartile range
(e.g. time to reach full enteral nutrition). Binary outcomes
(e.g. incidence of NEC) will be presented as counts and
percentages.
To make a preliminary test of the effects of the inter-
vention with BCF, clinical and paraclinical outcomes will
be compared between the two groups. The estimates will
be presented as relative risk and absolute risk difference,
difference between means or hazard ratio, depending on
the type of outcome. The estimates will be presented with
a 95% confidence interval. Regression models, logistic re-
gression for binary outcomes and Cox regression for time
to event outcomes will be used to evaluate the outcomes
of interest between the two groups, adjusting for SGA
(stratification variable) and covariates that are known to
be prognostic in relation to the outcome variable (e.g. ges-
tational age, birth weight and sex). A Fine–Gray regres-
sion, taking competing risk of infant death into account,
will be carried out as a sensitivity analysis for time to
event outcomes. If relevant, sensitivity analyses will be
conducted using multiple imputations to explore the
potential impact of missing data. Results from all these
analyses will be considered preliminary since this a
pilot-scale trial. The feasibility of the study will be
presented as categorical variables with three levels as
displayed in Table 3.
Ethics approval and consent to participate
The trial (version 2 of the protocol) has been approved by
the Regional Scientific Ethical Committee of Southern
Denmark on November 28, 2017 (S-20130010) and the
Danish Data Protection Agency on October 4, 2017 (2008-
58-0035), and registered at ClinicalTrials.gov (NCT035
37365).
Parents will be given oral and written information about
the trial, including its purpose, risk and benefits. They will
be given sufficient time to consider participation in the
trial and to have their questions answered. Written in-
formed consent must be provided before implementation
of study procedures (e.g. randomisation and blood test).
The parents may withdraw their infant(s) from the trial
for any reason at any time. Similarly, investigators may
withdraw one or more infants, according to clinical judg-
ments and safety assessment, or if the parents are
Table 3 Pre-defined criteria used to decide whether, or how, to
proceed with a later, larger randomised control trial. Green
colour: Fully acceptable and feasible. Yellow colour: Feasibility
concern, changes to be decided. Red colour: Serious feasibility
concerns, clear actions must be taken before a greater
randomised control trial is planned
Consent rate > 70% 50–70% < 50%
Recruitment rate > 50% 20–50% < 20%
Proportion of incomplete datasets < 20% 20–50% > 50%
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unwilling to comply with required study procedures, or if
the trial is terminated early for any reason.
Data monitoring
Adverse event reporting
Very preterm infants are often seriously ill and both
adverse and serious adverse events may occur during
hospitalisation. All unexpected adverse events (related or
unrelated to intervention) will be recorded in the case
report form, including information on type of event, date of
onset, end date, intensity (mild, moderate, severe), severity
(yes/no) and their presumed relation to the intervention
(yes/no). Serious adverse events and all suspected unex-
pected serious adverse reactions (SUSARs), suspected to
relate to the BCF intervention or the BMF control group
will be reported to the coordinating investigator and the
sponsor within 24 h after the local principal investigator
becomes aware of the event. The coordinating investigator
is responsible for informing the Scientific Ethical Commit-
tee and the Data Safety Monitor Board of any SUSARs that
occur during the trial.
Data Safety Monitor Board
An independent Data Safety Monitor Board (DSMB) is
established to assess the trial progress and to ensure inde-
pendent evaluation of possible harm to participants. The
DSMB consists of three members who are respective
experts in neonatology, biostatistics and methodology in
clinical trials. Three pre-planned DSMB meetings are held
during the recruitment period. Unscheduled meetings will
be held if the coordinating investigator or the sponsor
consider it necessary, e.g. if an unexpected high number of
NEC or SUSARs, possibly related to the intervention, are
reported. The primary role of the DSMB is to provide
recommendations regarding trial modification, continu-
ation or termination.
Discussion
Human milk is well documented to provide the best pro-
tection against feeding intolerance, NEC and LOS [45], yet
it does not contain enough nutrients to support growth
according to current guidelines. Therefore, nutrient fortifi-
cation of mother’s own milk and/or human donor milk
has become common practice in neonatal units around
the world [46]. However, it remains unclear when, how
and with what product human milk should be fortified.
Fortification can be done using widely different strategies
[45]. Fortification is typically initiated when human milk
intake reaches 100–140mL/kg/day, with consideration of
infant age and maturity. Some units practice early start of
fortification, at low volumes of enteral feed (from 50mL/
kg/day), while other units do not start until later and at
higher feeding volumes (e.g. at 150–160mL/kg/d), often
related to a fear of feeding intolerance and NEC. Both
standard fortification (i.e. same amount of protein given
to all infants) and individualised fortification (i.e. fortifica-
tion adjusted to protein contents in human milk for each
infant) are practiced. Further, some units use BUN values
to start and adjust fortification (e.g. 3.2–5.0mmol/L as
target values [47, 48]), some start with full-strength fortifi-
cation, while others start with half-strength fortification
and increase to full-strength within some days [49].
Therefore, a better understanding of the optimal way to
fortify human milk for very preterm infants is needed.
In this study, we chose to start fortification with BCF or
BMF at a feeding volume of 100mL/kg/day and no later
than 140mL/kg/day, if possible according the BUN values.
Together with the current international guidelines for
nutrient fortification, these criteria were chosen to make
the procedures similar among the participating units. In
Denmark, an enteral feeding volume of 150–160mL/kg/
day is generally reached for very preterm infants 7–12
days after birth (unpublished data). A specific age (num-
ber of days since birth) at initiation of fortification was not
a criterion in this trial because we believe that the actual
achieved feeding volume is a better marker of adequate
gut maturity than infant age.
Included infants are born at different gestational ages (26
+ 0 to 30 + 6 weeks) and it is well known that the smallest
and most immature infants are the most challenging to feed
due to feeding intolerance and co-morbidities increasing
the risk of postnatal growth failure. Therefore, they would
presumably also be the infants to benefit the most from a
milk diet that may be more protective for the immature
gastrointestinal tract. For safety reasons, we decided to start
fortification only when BUN values are below 5mmol/L.
However, it remains unclear if a moderately elevated BUN
value has any relation to common complications such as
kidney immaturity, metabolic dysfunctions or protein
overload [47]. Further studies are required to understand
the predictive value of BUN measurements to guide nutri-
ent fortification for very preterm infants.
The concept of feeding intolerance is a key issue when
discussing different strategies to fortify human milk. Feed-
ing intolerance is not a well-defined clinical parameter and
a variety of methods are used to help assess if the infant ap-
pears intolerant to enteral feeding. Several studies indicate
that the volume and colour of gastric residuals is a poor in-
dicator of feeding intolerance and early signs of NEC [48,
50]. In this pilot trial, we will also evaluate possible signs of
feeding intolerance by registering both the colour and
volume of gastric residuals and number of days to 50% and
to full enteral feeding. Feeding intolerance might be due to
increased osmolarity when adding fortifiers to human milk
above the accepted upper limit (< 400mOsm/L) [51],
although the evidence in support of this upper limit is
weak. Prior to our study, we investigated the osmolarity in
banked human donor milk (from Hvidovre Hospital,
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Hvidovre, Denmark) before fortification (295mOsm/L)
and after fortification with either BCF (28 g/L, 334mOsm/
L) or BMF (40 g/L, 409mOsm/L). These values did not in-
crease during 24 h storage at 4 °C; hence, high feed osmo-
larity is unlikely to be a problem in any of the groups in
our study.
The secondary and paraclinical endpoints in this pilot
trial aimed to support the preliminary observations regard-
ing the clinical effects of the two different fortifiers on gut
metabolism, function and immunity. Plasma amino acid
levels are relevant to record because certain amino acids
can be used to indicate protein overload (e.g. tyrosine)
while others may reflect improved gut function and
immunity (e.g. arginine, citrulline) [28–31]. Plasma levels of
neutrophil extracellular trap components, lactoferrin and
ILs, especially IL-6 and IL-8, are used to assess systemic
immunity and inflammation, and thereby sepsis resistance
[52]. Faecal composition and diversity of microbiota and of
IL-8, calprotectin (S100-A8/9) and bacterial metabolites
(short-chain fatty acids) are measured to reflect how each
of the fortification products affect the local gut environ-
ment, bacterial metabolism and immunity.
Collectively, our protocol provides both clinical and
paraclinical endpoints to test the feasibility, safety and
preliminary efficacy of a novel nutrient fortifier for very
preterm infants.
Study status
Recruitment is ongoing at eight neonatal departments in
Denmark. The first infant was recruited on December
14, 2017, and we expect to complete recruitment within
2 years. Please see SPIRIT Checklist for FortiColos: Rec-
ommended items to address in a clinical trial protocol
and related documents (Additional file 1).
Additional file
Additional file 1: SPIRIT Checklist for FortiColos: Recommended items to
address in a clinical trial protocol and related documents. (DOCX 58 kb)
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